Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor decided to discontinue ALX-0171 development (due to insufficient evidence of efficacy). As a result, the ALX0171-C203 study was early terminated.

Conditions

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Interventions

BIOLOGICAL: ALX-0171 1.5 mg/kg
OTHER: Placebo

Sponsor

Ablynx, a Sanofi company